Left Menu
Development News Edition

Gilead cuts 2020 sales outlook as COVID-19 drug remdesivir falls short

Remdesivir brought in $873 million in the quarter, below analysts' estimates of $960 million, according to Refinitiv IBES data. Gilead Chief Commercial Officer Johanna Mercier said that although the United States saw a surge in COVID-19 cases over the summer, many were younger people and hospitalization rates actually dropped.

Reuters | Updated: 29-10-2020 04:10 IST | Created: 29-10-2020 04:10 IST
Gilead cuts 2020 sales outlook as COVID-19 drug remdesivir falls short

Gilead Sciences Inc on Wednesday cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID-19. Remdesivir brought in $873 million in the quarter, below analysts' estimates of $960 million, according to Refinitiv IBES data.

Gilead Chief Commercial Officer Johanna Mercier said that although the United States saw a surge in COVID-19 cases over the summer, many were younger people and hospitalization rates actually dropped. "Our assumption is in light of the surge this fall both in Europe and the U.S., those numbers will pop back up," she said. Gilead lowered the top end of its full-year sales outlook to $23.5 billion, which is below Wall Street estimates of $24.1 billion. The company had previously forecast 2020 sales as high as $25 billion.

"The revision in guidance is tied, not entirely, but almost entirely to expectations around Veklury," Gilead Chief Financial Officer Andrew Dickinson said, using the brand name for remdesivir. "There was less demand in the third quarter than expected." Remdesivir is authorized or approved for use in more than 50 other countries around the world. It was one of the treatments given to U.S. President Donald Trump during his recent bout with COVID-19.

Gilead said some sales recorded in the third quarter are being held in inventory for use in the fourth quarter, and the volume of remdesivir purchased for government stockpiling purposes fell short of what the company had projected. Remdesivir has become the standard of care for patients hospitalized with severe COVID-19, but many U.S. doctors remain wary of using it in patients with less severe illness.

"There is still uncertainty about the pandemic and still lingering questions about the visibility of remdesivir with antibodies coming," Jefferies analyst Michael Yee said, referring to experimental antibody drugs designed to treat COVID-19. Gilead shares, which closed down 2%, fell another 1.5% in extended trading.

Third-quarter revenue of $6.6 billion beat the average analysts' estimate of $6.31 billion. The company posted adjusted earnings per share of $2.11, topping Wall Street expectations by 21 cents. Sales of the company's flagship HIV drugs rose 8% from a year earlier to $4.55 billion, as patient demand normalized following disruption related to the pandemic.

Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial. Commercial sales began in July and the FDA formally approved the drug this month, despite recent results from a World Health Organization-sponsored trial showing remdesivir did not improve patient outcomes.


TRENDING

OPINION / BLOG / INTERVIEW

Turbulence surrounding tobacco control in Ghana

... ...

Smart healthcare: IoT redefining the way healthcare is delivered

As the world is embracing the new wave of digitalization triggered by the pandemic and the arrival of 5G, the adoption of IoT devices will further boom. With adoption set to soar, IoT security issues and other challenges cant be ignored any...

Refugee compassion and response: Ideas to mitigate disasters now and in their future

Their homeland becomes a forbidden territory for them and more likely than not, their journey to foreign soil is no less traumatizing, not to say deadly. It is crucial to help refugees live a life of dignity and purpose....

Inadequate water infrastructure causes a tidal wave of coronavirus in rural Alaska

... ...

Videos

Latest News

New York City public schools will begin to reopen with weekly COVID-19 testing

New York Citys public schools will begin to reopen for in-person learning on Dec. 7, starting with elementary schools for students whose parents agree to a weekly testing regimen for the novel coronavirus, Mayor Bill de Blasio announced on ...

1 inmate dead, 3 wounded in Sri Lanka prison riot

At least one inmate was killed and three others injured on Sunday when inmates clashed with the prison officers at a facility on the outskirt of the capital Colombo, officials said. Police spokesman Ajith Rohana said inmates created unrest ...

Banda district admin asks UP govt to set up raw material godown for shazar stone traders

The district administration here has requested the Uttar Pradesh government to build a godown to relieve the artisans engaged in making the districts famed shazar stones from the difficulty of procuring the raw materials, an official said o...

U.S. CDC reports 265,166 deaths from coronavirus

The U.S. Centers for Disease Control and Prevention CDC on Sunday reported a total 13,142,997 cases of new coronavirus, an increase of 143,333 from its previous count, and said the number of deaths had risen by 1,210 to 265,166.The CDC repo...

Give Feedback